Investigational Site Number : 4100012

Gwangju, Gwangju 61453

1 studies enrolling now · 2 studies all time

What they study most

Dermatitis Atopic

Studies at this site

• A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis — Running, not enrolling
• Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials — Enrolling by invitation